{"id":"seretide-250-placebo-via-synchro-breathe","safety":{"commonSideEffects":[{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Palpitations"},{"rate":null,"effect":"Oral candidiasis"},{"rate":null,"effect":"Nervousness/anxiety"}]},"_chembl":{"chemblId":"CHEMBL3663534","moleculeType":"Small molecule","molecularWeight":"402.38"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fluticasone propionate suppresses inflammatory responses in the airways by binding glucocorticoid receptors, reducing mucus production and airway edema. Salmeterol activates beta-2 adrenergic receptors on bronchial smooth muscle, causing sustained bronchodilation. Together, they provide both anti-inflammatory and bronchodilatory effects for maintenance asthma and COPD control.","oneSentence":"Seretide combines fluticasone propionate (inhaled corticosteroid) and salmeterol (long-acting beta-2 agonist) to reduce airway inflammation and improve bronchial smooth muscle relaxation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:37:33.304Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Asthma maintenance therapy"},{"name":"Chronic obstructive pulmonary disease (COPD) maintenance therapy"}]},"trialDetails":[{"nctId":"NCT01194700","phase":"PHASE4","title":"Comparative Study of Lung Bioavailability of HFA-Seretide Via Current Spacer Devices in Healthy Volunteers","status":"COMPLETED","sponsor":"Brian J Lipworth","startDate":"2009-11","conditions":"Asthma","enrollment":19}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Advair"],"phase":"marketed","status":"active","brandName":"Seretide 250/placebo via Synchro-Breathe","genericName":"Seretide 250/placebo via Synchro-Breathe","companyName":"Brian J Lipworth","companyId":"brian-j-lipworth","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Seretide combines fluticasone propionate (inhaled corticosteroid) and salmeterol (long-acting beta-2 agonist) to reduce airway inflammation and improve bronchial smooth muscle relaxation. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}